TSOT137: "Still Take It, But... In Smaller Doses." The History Repeat of AZT and GLPs

The adjustment in marketing strategy and dosage that helps prove the point of the dangers they're perfectly well aware of but don't care about.Plus some refresh on background covered in other episodes on same topic. BTW, in my off-top-of-head examples of clear indications, I didn't mention among others, ACUTE PANCREATITIS, which may require emergency treatment to avoid DEATH.But, oh yeah, it's science's "miracle drug."(A good general rule by the way is to just say "toxin" whenever you see "drug". It's not always true but is as often as not.)  ===========================Popular weight loss drugs linked to rare but severe stomach problems, study finds"The new research, based on health insurance claims from 2006 to 2020 from more than 5,000 patients in the U.S., looked at how many people developed one of four serious gastrointestinal problems — biliary disease, gastroparesis, pancreatitis or bowel obstructions — after they were prescribed one of the weight loss drugs. About 4,100 of the patients were prescribed liraglutide, about 600 semaglutide and 650 the weight loss drug bupropion-naltrexone, which is not a GLP-1 medication."..."People included in the analysis all had records of obesity and did not have diabetes, which itself can cause gastroparesis." =====================Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide"Question  Are prescriptions for semaglutide associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes or patients who are overweight or obese?"Findings  This matched cohort study of 16 827 patients revealed higher risk of NAION in patients prescribed semaglutide compared with patients prescribed non–glucagon-like peptide receptor agonist medications for diabetes or obesity."=============================The unseen risk of Ozempic: NAION and vision damage"According to a study, 6.7% of people who were overweight and 8.9% of those with diabetes who took semaglutide had NAION. The FDA issued a warning regarding counterfeit and compounded products while approving semaglutide for weight loss under the Wegovy® brand. Unsupervised usage and problems with diabetes accessibility raise ethical questions." . . ."Semaglutides cause NAION by vascular dysregulation at the optic nerve head, activation of GLP-1 receptors in retinal ganglion cells, and fast glycemic or weight changes that influence perfusion. Patients with packed optic discs or vascular risk factors may be more vulnerable[7]. Many experts are raising concerns about the potential risks that patients may face from these medications. These include side effects like muscle loss, severe side effects like pancreatitis, and kidney and gallbladder issues."================================= The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy "The human dosage is based on a study by the manufacturer of the drug and their collaborators, which reported in 1986 that the inhibitory dose for HIV replication was 0.05 to 0.5 microM AZT and that for human T-cells was 2000 to 20,000 times higher, i.e. 1000 microM AZT. This suggested that HIV could be safely inhibited in humans at 20 to 60 microM AZT. However, after the licensing of AZT as an anti-HIV drug, several independent studies reported 20- to 1000-fold lower inhibitory doses of AZT for human and animal cells than did the manufacturer's study, ranging from 1 to 50 microM. In accord with this, life threatening toxic effects were reported in humans treated with AZT at 20 to 60 microM." . .. "It is concluded that AZT, at the dosage prescribed as an anti-HIV drug, is highly toxic to human cells."